SCHEMBL8102001

SCHEMBL8102001

CCOC(=O)Cn1ccc(=O)c(O)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
TP53 P04637 1/20 0.51
CYP2D6 P10635 1/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
KDM6A O15550 1/20 0.46
KDM4A O75164 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
KDM5C P41229 1/20 0.46
KDM2B Q8NHM5 1/20 0.46
DOHH Q9BU89 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
ALDH1A1 P00352 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8611607 0.86 KDM4E (0.53) KDM4ETP53CYP2D6HTTSMN1; SMN2
SCHEMBL8106196 0.85 TNF (0.50) KDM4ETP53CYP2D6HTTSMN1; SMN2
Hydrochloric Acid SCHEMBL9010381 0.84 TNF (0.49) KDM4ETP53CYP2D6HTTSMN1; SMN2
SCHEMBL20382962 0.83 HTT (0.62) KDM4ETP53CYP2D6HTTSMN1; SMN2
SCHEMBL27481987 0.81 CYP2C19 (0.41) KDM4ETP53CYP2D6HTTSMN1; SMN2
SCHEMBL3083137 0.80 KDM4E (0.61) KDM4ETP53CYP2D6HTTSMN1; SMN2
SCHEMBL18379543 0.80 KDM4E (0.57) KDM4ETP53CYP2D6HTTSMN1; SMN2
SCHEMBL27464130 0.79 PPARG (0.45) KDM4ETP53CYP2D6HTTSMN1; SMN2
SCHEMBL13856905 0.79 KDM4E (0.55) KDM4ETP53CYP2D6HTTSMN1; SMN2
SCHEMBL5525055 0.78 KDM4E (0.62) KDM4ETP53CYP2D6HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0305646-A2 3-Hydroxypyrid-4-ones and pharmaceutical compositions BTG INTERNATIONAL LIMITED (GB) 1989-03-08 EP claimed
EP-0120669-A2 Hydroxypyridones, and their pharmaceutical compositions NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-10-03 EP claimed
US-RE36831-E TREATMENT OF IRON DEFICIENCY ANEMIA BRITISH TECHNOLOGY GROUP LTD. (GB) 2000-08-22 US disclosed
US-5814614-A Substituted glucose compounds for toxic metal ion removal from the body KRUCK THEO P A (CA) 1998-09-29 US disclosed
EP-0305646-A2 3-Hydroxypyrid-4-ones and pharmaceutical compositions BTG INTERNATIONAL LIMITED (GB) 1989-03-08 EP disclosed
US-4650793-A NITROGEN-SUBSTITUTED NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1987-03-17 US disclosed
EP-0120669-A2 Hydroxypyridones, and their pharmaceutical compositions NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-10-03 EP disclosed
EP-0120670-A1 Iron III complexes of hydroxypyridones, and their pharmaceutical compositions NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-10-03 EP disclosed